Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

About this update from Aethlon Medical, Inc.

[{"type":"text","content":" Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call to be Held Today at 4:30 p.m. ET","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.","length":354,"tagName":"p"},{"type":"text","content":"Key Fiscal 2025 Highlights","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First three patients treated in Hemopurifier® cancer trial at Australian sites","length":78,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":78,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Indian regulatory approval received to initiate a similar oncology study","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":72,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study protocol expanded to reflect evolving immunotherapy standard of care","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":74,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical data demonstrate 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":103,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration with UCSF to investigate Long COVID with findings to be presented at the Keystone Symposium","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":105,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Operating expenses reduced significantly through streamlined operations","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":71,"olType":false},{"type":"text","content":"Clinical Progress in Cancer Trial","length":33,"tagName":"p"},{"type":"text","...

More updates from Aethlon Medical, Inc.